Serum uric acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease

International Heart Journal

Volumn 48, Issue 4, 2007, Pages 523-532

  Njaman, Widi ^a   Iesaki, Takafumi ^a   Iwama, Yoshitaka ^a   Takasaki, Yoshinari ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Connective tissue disease; Prognosis; Pulmonary arterial hypertension; Serum uric acid

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGITALIS; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; STEROID; URIC ACID;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL RATE; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; CONNECTIVE TISSUE DISEASES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; URIC ACID;

EID: 34648824675     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.523     Document Type: Article

References (34)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7. (Review)
2. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1 Suppl): 35S-62S.
3. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsqer TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
4. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.
5. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
6. Sanchez O, Humbert M, Sitbon O, Simonneau G Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-7. (Review)
7. Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993; 2: 367-9.
8. Alpert MA, Pressly TA, Mukerji V, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991; 68:1687-91.
9. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-65.
10. Hayabuchi Y, Matsuoka S, Akita H, Kuroda Y. Hyperuricaemia in cyanotic congenital heart disease. Eur J Pediatr 1993; 152: 873-6.
11. Braghiroli A, Sacco C, Erbetta M, Ruga V, Donner CF. Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. Am Rev Respir Dis 1993; 148: 173-8.
12. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys 1993; 302: 228-32.
13. Hasday JD, Grum CM. Nocturnal increase of urinary uric acid: creatinine ratio. A biochemical correlate of sleep-associated hypoxemia. Am Rev Respir Dis 1987; 135: 534-8.
14. Jossa F. J, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677-81.
15. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-92.
16. Oya H, Nagaya N, Satoh T, et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000; 84: 53-8.
17. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-62.
18. Domagk G; Schlicke HH. A colorimetric method using uricase and peroxidase for the determination of uric acid. Anal Biochem 1968; 22: 219-24.
19. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-24.
20. Voelkel. MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuncemia in severe pulmonary hypertension. Chest 2000; 117: 19-24.
21. Galie N, Manes A, Faraham KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005; 14: 713-7.
22. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-63. (Review)
23. Fox AC, Reed GE, Meilman H, et al. Release of nucleosides from canine and human hearts as an index of prior ischemia. Am J Cardiol 1979; 3: 52-8.
24. Mentzer RM Jr, Rubio R, Berne RM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol 1975; 229: 1625-31.
25. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7.
26. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006; 62: 1-12.
27. Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004; 169: 764-9.
28. Robbins IM, Morrow JD, Christman BW. Oxidant stress but not throniboxane decreases with epoprostenol therapy. Free Radic Biol Med 2005; 38: 568-74.
29. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-8.
30. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 12: 48S-55. (Review)
31. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibresing alveolitis. Rheumatology 2002; 41: 676-9.
32. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54: 184-91.
33. Yamanaka A, Tasaki H, Suzuki Y, et al. Bosentan improved syncope in a hemodialysis patient with pulmonary hypertension and mild aortic stenosis. Int Heart J 2006; 47: 911-7.
34. Torbicki A, Skwarski K, Hawrylkiewicz I, Pasierski T, Miskiewicz Z, Zielinski J. Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. Eur Respir J 1989; 2: 856-60.